Newswise — New York, NY (October 22, 2025) – The Mount Sinai Tisch Cancer Center (TCC) has been named a “Comprehensive Cancer Center” by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and affirms the breadth and depth of its cancer research, clinical excellence, and commitment to health equity. The designation also brings more than $3 million annually to support Mount Sinai’s research and innovation.
Founded in 2008, The Mount Sinai Tisch Cancer Institute first received NCI “Clinical Cancer Center” status in 2015. After a decade of growth in research, clinical trials, and community outreach, Mount Sinai became eligible to apply for Comprehensive Cancer Center designation in 2024. The elevation to this status reflects Mount Sinai’s remarkable trajectory, which also includes The Mount Sinai Hospital’s ranking as No. 6 nationally for cancer care by U.S. News & World Report and Mount Sinai Tisch Cancer Center’s position as No. 11 in the country for National Cancer Institute research funding.
Through advances in translational science, multidisciplinary collaboration, infrastructure investment, and a focus on equity in cancer care, Mount Sinai positioned itself to meet NCI hallmarks of a designated Comprehensive Cancer Center: “added depth and breadth of research” and “substantial transdisciplinary research.”
“This designation is a testament to the dedication and brilliance of our faculty, staff, students, and patients,” said Ramon E. Parsons, MD, PhD, Director of The Tisch Cancer Institute and Dean for Cancer Research at the Icahn School of Medicine at Mount Sinai. “It affirms Mount Sinai’s role not only as a place of scientific discovery but as a leader in bringing those discoveries to our patients.”
“Receiving the Comprehensive Cancer Center designation from the NCI is a pivotal moment,” said Eric J. Nestler, MD, PhD, Dean of the Icahn School of Medicine at Mount Sinai. “It underscores our sustained investment in cancer science, our commitment to training the next generation of investigators, and our promise to improve cancer care not just here in New York, but nationally and globally.”
Researchers at TCC have led transformative studies across a wide spectrum of cancers, advancing treatments that are changing standards of care worldwide:
Together, these studies highlight the scientific excellence, innovation, and patient-centered focus that underpin Mount Sinai’s recognition by the National Cancer Institute as a Comprehensive Cancer Center.
“This recognition places Mount Sinai among the nation’s leaders in cancer discovery and care,” said Brendan G. Carr, MD, MA, MS, Chief Executive Officer of the Mount Sinai Health System, and Professor and Kenneth L. Davis, MD, Distinguished Chair. “Mount Sinai’s leadership in leading-edge trials, translational science, and community-engaged prevention efforts has earned this hard-won recognition. We are grateful for the work of so many: researchers, clinicians, staff, and our patient partners who have made this possible.
“This designation raises the bar for what we can achieve,” Dr. Carr added. “We will continue striving for breakthroughs that change lives and bring hope to patients everywhere.”
This designation is supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA196521.
###
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
——————————————————-
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
https%3A%2F%2Fwww.newswise.com%2Farticles%2Fmount-sinai-tisch-cancer-center-receives-comprehensive-cancer-center-designation-and-funding-from-national-cancer-institute%2F%3Fsc%3Drsla
The post Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding from National Cancer Institute appeared first on CliQ INDIA.
Contact to : xlf550402@gmail.com
Copyright © boyuanhulian 2020 - 2023. All Right Reserved.